Department of Dermatology, Charles Nicolle Hospital, Tunis, Tunisia.
Department of Dermatology, CHU Farhat Hached, Sousse, Tunisia.
J Cosmet Dermatol. 2021 Oct;20(10):3324-3329. doi: 10.1111/jocd.14209. Epub 2021 May 25.
Treatment options for erythematotelangiectatic rosacea (ETR) are still scarce. Tranexamic acid (TXA) is an antifibrinolytic drug that was recently used for the treatment of ETR.
To evaluate the efficacy and safety of intradermal microinjections of TXA for ETR.
PATIENTS/METHODS: This was a retrospective study enrolling patients, treated with TXA intradermal microinjections for ETR, from January 2019 to February 2020. Response to treatment was assessed based on subjective symptoms, clinical photographs, and the Investigator Global Assessment of Rosacea Severity Score (IGA-RSS).
Six patients were included. The mean number of monthly intradermal TXA microinjections was 5.1 ± 1.3. The mean decrease of IGA-RSS was 2.4 ± 0.5. Local side effects, mainly transient erythema and swelling, were noticed in three cases. No systemic effects were noted. Clinical improvement, in respondent patients, lasted after 3 months of follow-up.
Intradermal TXA microinjections are a safe and effective treatment option for ETR. The optimal number of monthly sessions has yet to be determined.
红斑毛细血管扩张型酒渣鼻（ETR）的治疗选择仍然有限。氨甲环酸（TXA）是一种抗纤维蛋白溶解药物，最近被用于治疗 ETR。
评估 TXA 皮内微注射治疗 ETR 的疗效和安全性。
患者/方法：这是一项回顾性研究，纳入了 2019 年 1 月至 2020 年 2 月期间接受 TXA 皮内微注射治疗 ETR 的患者。根据主观症状、临床照片和研究者酒渣鼻严重程度整体评估（IGA-RSS）评估治疗反应。
共纳入 6 例患者。每月皮内 TXA 微注射的平均次数为 5.1±1.3。IGA-RSS 的平均下降值为 2.4±0.5。3 例患者出现局部不良反应，主要为短暂性红斑和肿胀。未观察到全身不良反应。应答患者的临床改善在随访 3 个月后仍持续存在。
TXA 皮内微注射是治疗 ETR 的一种安全有效的治疗选择。每月治疗次数的最佳次数仍有待确定。
